Adenovirus E1A oncogene expression in tumor cells enhances killing by TNF-related apoptosis-inducing ligand (TRAIL)

Journal of Immunology

Volumn 165, Issue 8, 2000, Pages 4522-4527

  Routes, J M ^a   Ryan, S ^a   Clase, A ^a   Miura, T ^a   Kuhl, A ^a   Potter, T A ^a   Cook, J L ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIGAND; TUMOR NECROSIS FACTOR;

ADENOVIRUS; APOPTOSIS; ARTICLE; CELL KILLING; CYTOLYSIS; FIBROSARCOMA; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LIGAND BINDING; PRIORITY JOURNAL; TUMOR CELL;

EID: 0034667997     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.165.8.4522     Document Type: Article

References (70)

1. The Seattle Virus Watch. VII. Observations of adenovirus infections
2. The virus watch program: A continuing surveillance of viral infections in metropolitan New York families
3. Analysis of human tonsil and cancer DNAs and RNAs for DNA sequences of group C (serotypes 1, 2, 5 and 6) human adenovirus
4. Transformation by and oncogenicity of human adenoviruses
5. E1A gene expression induces susceptibility to killing by NK Cells following immortalization but not adenovirus-infection of human cells
6. E1A oncogene induction of cellular susceptibility to killing by cytolytic lymphocytes through target cell sensitization to apoptotic injury
7. Immunological surveillance against DNA virus-transformed cells: Correlations between natural killer cell cytolytic competence and tumor susceptibility of athymic rodents
8. Adenovirus E1A gene induction of susceptibility to lysis by natural killer cells and activated macrophages in infected rodent cells
9. E1A oncogene expression in target cells induces cytolytic susceptibility at a post-recognition stage in the interaction with killer lymphocytes
10. Role of tumor necrosis factor-α in E1A oncogene-induced susceptibility of neoplastic cells to lysis by natural killer cells and activated macrophages
11. Adenovirus E1A renders infected cells sensitive to cytolysis by tumor necrosis factor
12. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family
13. Identification and characterization of a new member of the TNF family that induces apoptosis
14. The receptor for the cytotoxic ligand TRAIL
15. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors
16. TRAIL-R2: A novel apoptosis-mediating receptor for TRAIL
17. A novel receptor for Apo2L/TRAIL contains a truncated death domain
18. Cutting edge: Lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): A new receptor protecting lymphocytes from the death ligand TRAIL
19. An antagonist decoy receptor and a death domain-containing receptor for TRAIL
20. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL
21. TRAIL: A molecule with multiple receptors and control mechanisms
22. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo
23. IFN-γ mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression
24. + T cell-mediated cytotoxicity
25. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma
26. Antioncogenic effect of adenovirus E1A in human tumor cells
27. Isolation of deletion and subsitution mutants of adenovirus type 5
28. Adenovirus transforming 19-kD antigen has an enhancer-dependent transactivation function and relieves enhancer repression mediated by viral and cellular genes
29. Monoclonal antibodies specific for adenovirus early region 1A proteins: Extensive heterogeneity in early region 1A products
30. Tumorigenicity of adenovirus-transformed cells; region E1A of adenovirus 12 confers resistance to natural killer cells
31. An inverse relation of the oncogenic potential of adenovirus-transformed cells and their sensitivity to killing by syngeneic natural killer cells
32. Adenovirus persistence in man: Defective E1A gene product targeting of infected cells for killing by natural killer cells
33. Immune evasion by adenoviruses
34. A 14,700 MW protein from the E3 region of adenovirus inhibits cytolysis by tumor necrosis factor
35. The E1B 19,000-molecular-weight protein of group C adenoviruses prevents tumor necrosis factor cytolysis of human cells but not of mouse cells
36. The 10,400- and 14,500-dalton proteins encoded by region E3 of adenovirus function together to protect many but not all mouse cell lines against lysis by tumor necrosis factor
37. E1B 19K inhibits Fas-mediated apoptosis through FADD-dependent sequestration of FLICE
38. The adenovirus E3-10. 4K/14.5K complex mediates loss of cell surface Fas (CD95) and resistance to Fas-induced apoptosis
39. Forced degradation of Fas inhibits apoptosis in adenovirus-infected cells
40. Identification of a cell protein (FIP-3) as a modulator of HF-kB activity and as a target of an adenovirus inhibitor of tumor necrosis factor α-induced apoptosis
41. Adenovirus early region 1A modulation of interferon antiviral activity
42. Adenovirus VAI RNA antagonizes the antiviral action of interferon by preventing activation of the interferon-induced eIF-2α kinase
43. 'E3/19K' protein of adenovirus type 2 inhibits lysis of cytolytic T lymphocytes by blocking cell surface expression of histocompatibility class I antigen
44. Isolation and characterization of four adenovirus type 12-transformed human embryo kidney cell lines
45. Modulation of the level of expression of cellular genes in adenovirus 12-infected and transformed human cells
46. Transformation of human embryo retinoblasts with simian virus 40, adenovirus and ras oncogenes
47. Characteristics of a human cell line transformed by DNA from human adenovirus type 5
48. Adenovirus E1A inhibits IFN-induced resistance to cytolysis by natural killer cells
49. Interferon increases class I MHC Ag expression on adenovirus infected human cells without inducing resistance to NK cell killing
50. Recognition of adenovirus E1A gene products on immortalized cell surfaces by cytotoxic T lymphocytes
51. Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes
52. Anti-adenovirus type 5 cytotoxic T lymphocytes: Immunodominant epitopes are encoded by the E1A gene
53. b, but not in H-2(d) or H-2(k) mice
54. The routine cellular immune response to adenovirus type 5
55. Resistance of human cells to the adenovirus E3 effect on class I MHC antigen expression: Implications for antiviral immunity
56. + T-cell responses are not inhibited by E3-19K in the presence of γ interferon
57. E1A oncogene expression level in sarcoma cells: An independent determinant of cytolytic susceptibility and tumor rejection
58. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer
59. Regulation of apoptosis by adenovirus E1A and E1B oncogenes
60. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells
61. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
62. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
63. Age-related and thymus-dependent rejection of adenovirus 2-transformed cell tumors in the Syrian hamster
64. E1A oncogene induction of cytolytic susceptibility eliminates sarcoma cell tumorigenicity
65. Tumorigenicity of adenovirus-transformed cells and their sensitivity to tumor necrosis factor α and NK/LAK cell cytolysis
66. Natural killer cell ontogeny in the athymic rat: Relationship between functional maturation and acquired resistance to E1A oncogene-expressing sarcoma cells
67. E1A oncogene-induced cellular sensitization to immune-mediated apoptosis is independent of p53 and resistant to blockade by E1B 19 kDa protein
68. p53-Dependent apoptosis modulates the cytotoxicity of anticancer agents
69. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL